These results suggest that FFA2 is normally expressed in β-cells, and that its activity is essential for β-cell compensation in response to obesity in mass and insulin secretion through Gαq/11- and PLC-mediated IP3/Ca2+ pathways; thus, it is a potential therapeutic target [36]. The gene discussed is GNAQ; the disease is obesity due to melanocortin 4 receptor deficiency.